Comorbid autoimmune diseases in patients with vitiligo: A cross-sectional study - 15/01/16
Abstract |
Background |
Few large-scale studies have quantified the burden of comorbid autoimmune diseases in patients with vitiligo.
Objective |
We sought to determine the prevalence of comorbid autoimmune diseases in patients with vitiligo.
Methods |
We conducted a manual chart review on a cohort of 1873 patients with vitiligo seen between January 2002 and October 2012 at the Henry Ford Health System in Detroit, MI. Patients were excluded if they had fewer than 2 dermatology notes (N = 595) or if they were never given a diagnosis of vitiligo by a dermatologist (N = 180).
Results |
Of 1098 patients with vitiligo, nearly 20% had at least 1 comorbid autoimmune disease. Compared with the general US population, we found a higher prevalence of thyroid disease (12.9%, P < .001), alopecia areata (3.8%, P < .001), inflammatory bowel disease (0.9%, P = .046), pernicious anemia (0.5%, P = .007), systemic lupus erythematosus (0.3%, P = .048), Guillain-Barre syndrome (0.3%, P < .001), discoid lupus (0.2%, P = .003), linear morphea (0.2%, P < .001), myasthenia gravis (0.2%, P = .002), and Sjögren syndrome (0.2%, P = .011).
Limitations |
The study lacked a control group. This was a single-institution study with possible selection bias, and thus the findings may not be representative of the overall population of patients with vitiligo.
Conclusions |
We observed a high prevalence of comorbid autoimmune diseases in patients with vitiligo and report several new associations.
Le texte complet de cet article est disponible en PDF.Key words : alopecia areata, associations, autoimmune disease, comorbidities, prevalence, thyroid disease, vitiligo
Abbreviations used : BSA, IBD, SLE, TPO, TSH, T1DM
Plan
Funding sources: None. |
|
Conflicts of interest: None declared. |
Vol 74 - N° 2
P. 295-302 - février 2016 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?